Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC

Sponsor
Hunan Province Tumor Hospital
Study ID
NCT05296278
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This study aimed to explore the efficacy and biomarker explanation of IBI-323 combined with bevacizumab plus platinum based chemotherapy on ALK-rearranged non-small cell lung cancer who failed from first line Alectinib.

Key Dates

First listed
Mar 25, 2022
Start date
Dec 25, 2023
Status verified
Jan 2024
Primary completion
Dec 10, 2025
Completion
Apr 1, 2026

Study Design

Enrollment
70 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort A
    patients with only 3'ALK confirmed by NGS
  • Experimental: Cohort B
    patients with 3'ALK with retention of 5'ALK

Primary Outcome Measure

ORR [ Time Frame: 1 year ]

Central Contacts

Related Studies